B-cell maturation antigen

Jump to navigation Jump to search
VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human
BCMA TALL-1 binding domain
File:PDB 1oqd EBI.jpg
crystal structure of stall-1 and bcma
Identifiers
SymbolBCMA-Tall_bind
PfamPF09257
InterProIPR015337
SCOP1oqd
SUPERFAMILY1oqd

B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene.

TNFRSF17 is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF).[1][2][3]

Function

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.[3]

Interactions

TNFRSF17 has been shown to interact with the B-cell activating factor TNFSF13B.[4][5] A conserved domain at the N-terminus, BCMA TALL-1 binding domain, is required for binding to the TNFSF13B.[4]

Clinical significance - Related Diseases

TNFRSF17 is implicated in leukemia, lymphomas, and multiple myeloma [6] (see the "Mitelman Database" [7] and the Atlas of Genetics and Cytogenetics in Oncology and Haematology,[8]).

As a drug target

In 2017, a phase 1 clinical trial employed a CAR-T therapy that targeted BCMA02 in multiple myeloma.[9] Side-effects seen include cytokine release syndrome and mild neurotoxicity.[10]

An antibody-drug conjugate GSK2857916 is in early clinical trials.[11][12] Side effects are expected to include corneal toxicity.[12]

References

  1. Laâbi Y, Gras MP, Carbonnel F, Brouet JC, Berger R, Larsen CJ, Tsapis A (Nov 1992). "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma". The EMBO Journal. 11 (11): 3897–904. PMC 556899. PMID 1396583.
  2. Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A (Apr 1994). "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed". Nucleic Acids Research. 22 (7): 1147–54. doi:10.1093/nar/22.7.1147. PMC 523635. PMID 8165126.
  3. 3.0 3.1 "Entrez Gene: TNFRSF17 tumor necrosis factor receptor superfamily, member 17".
  4. 4.0 4.1 Liu Y, Hong X, Kappler J, Jiang L, Zhang R, Xu L, Pan CH, Martin WE, Murphy RC, Shu HB, Dai S, Zhang G (May 2003). "Ligand-receptor binding revealed by the TNF family member TALL-1". Nature. 423 (6935): 49–56. doi:10.1038/nature01543. PMID 12721620.
  5. Shu HB, Johnson H (Aug 2000). "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". Proceedings of the National Academy of Sciences of the United States of America. 97 (16): 9156–61. doi:10.1073/pnas.160213497. PMC 16838. PMID 10908663.
  6. "TNFRSF17 (tumor necrosis factor receptor superfamily, member 17)". atlasgeneticsoncology.org.
  7. "Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer".
  8. "Atlas of Genetics and Cytogenetics in Oncology and Haematology". atlasgeneticsoncology.org.
  9. "Study of bb2121 in Multiple Myeloma - Full Text View - ClinicalTrials.gov". Retrieved 2017-12-12.
  10. CAR T-cell therapy bb2121 shows promising efficacy for multiple myeloma
  11. Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
  12. 12.0 12.1 Early Promise for Experimental Antibody-Drug Conjugate in Multiple Myeloma

External links

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article incorporates text from the public domain Pfam and InterPro: IPR015337